XENT News and Press, Intersect ENT Inc. From 02/01/21

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financi...

Approval Establishes New S Code for PROPEL to Facilitate Specific Coding & Payment Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the...

Intersect ENT (XENT) expects Q4 revenue in the range of $27.7M to 28.1M (prior $27.0M to $28.6M) vs. a consensus of $27.65M.SINUVA recorded strong quarterly revenue of ~$2.5M vs. $1.7M in the prior quarter.VENSURE, for sinus balloon dilation, an acquired Fiagon product line, initiated U.S. sa...

- Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million - Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced preliminary fourt...

Presentation time in the release dated December 17, 2020, should read 2 p.m. ET (instead of 5 p.m. ET). The updated release reads: INTERSECT ENT TO PRESENT AT THE 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose an...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39 th Annual J.P. Morgan Healthcare Conference. Tom West, President &...

Patrick Broderick to Serve as Executive Vice President, General Counsel and Corporate Secretary, and Reyna Fernandez Named as Chief Human Resource Officer Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions,...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that management will participate in the following upcoming investor conferences: Berenberg US CEO Conference 2020 Tom West...

Intersect ENT, Inc. (XENT) Q3 2020 Results Earnings Conference Call November 2, 2020, 8:30 AM ET Company Participants Randy Meier - Executive Vice President and CFO Tom West - President and CEO Conference Call Participants Robbie Marcus - JPMorgan Bob Hopkins - Bank of America Richard Newitte...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Overview Revenue of $22.7 million in...